TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36891761

Group type: EXPERIMENTAL
Intervention: Postoperative anaemia (lowest haemoglobin concentration < 11 g dl -1)
Number of subjects: 7940

Group type: EXPERIMENTAL
Intervention: Postoperative hypotension (SBP < 90 mmHg)
Number of subjects: 7940

Group type: EXPERIMENTAL
Intervention: Combination of postoperative anaemia and hypotension
Number of subjects: 7940

Group type: EXPERIMENTAL
Intervention: Postoperative anaemia and hypotension
Number of subjects: 7940
Study: 36891891

Group type: EXPERIMENTAL
Intervention: Digital impression
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alginate impression
Number of subjects: 24
Study: 36891906

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 117

Group type: COMPARATOR
Intervention: Antithrombotic therapy
Number of subjects: 117
Study: 36891909

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 31
Study: 36891979

Group type: EXPERIMENTAL
Intervention: High glycosylation group (elevated levels of CA19-9, CA125, or CEA)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: CA19-9
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: CA125
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: EGFR expression in high glycosylation pNENs
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: High glycosylation
Number of subjects: 322
Study: 36891995

Group type: EXPERIMENTAL
Intervention: Higher muscle mass assessed by creatinine excretion rate
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Higher muscle strength assessed by hand grip strength
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Muscle mass assessed by BIA
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Routine assessment using both 24-h urine samples and hand grip strength
Number of subjects: 741
Study: 36892042

Group type: EXPERIMENTAL
Intervention: Invasive left heart catheterization with left ventricular end-diastolic pressure measurement (≥16 mm Hg) for confirmation of HFpEF.
Number of subjects: 404
Study: 36892053

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Fried frailty scale
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Strength, assistance with walking, rising from a chair, climbing stairs, and falls scales
Number of subjects: 215
Study: 36892074

Group type: EXPERIMENTAL
Intervention: Objective sleep duration of 5 hours or shorter
Number of subjects: 5027

Group type: EXPERIMENTAL
Intervention: Self-reported short (≤4 hours) sleep duration on weekdays and weekends
Number of subjects: 5027

Group type: EXPERIMENTAL
Intervention: Self-reported long (>8 hours) sleep duration on weekdays and weekends
Number of subjects: 5027

Group type: EXPERIMENTAL
Intervention: Objective sleep duration
Number of subjects: 5027

Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration
Number of subjects: 5027
Study: 36892190

Group type: EXPERIMENTAL
Intervention: MW031 (60 mg)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Denosumab (60 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: MW031
Number of subjects: 119

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 119
Study: 36892220

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 123

Group type: COMPARATOR
Intervention: Slow-release misoprostol vaginal insert
Number of subjects: 123
Study: 36892506

Group type: EXPERIMENTAL
Intervention: UDCA-Fenofibrate group (fenofibrate at a daily dose of 200 mg in addition to UDCA)
Number of subjects: 117

Group type: COMPARATOR
Intervention: UDCA-only group (standard dose of UDCA)
Number of subjects: 117
Study: 36892545

Group type: EXPERIMENTAL
Intervention: CADe (EndoVigilant)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Non-CADe
Number of subjects: 769
Study: 36892565

Group type: EXPERIMENTAL
Intervention: 5-AZA/VEN (Azacitidine/Venetoclax)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAC-Score
Number of subjects: 0
Study: 36892600

Group type: EXPERIMENTAL
Intervention: Colorectal cancer surgery classified as R1 or R2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher TNM stage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher lymph node ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher Charlson comorbidity index score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASA IV classification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worse scores on EORTC and EQ-5D questionnaires
Number of subjects: 0
Study: 36892605

Group type: EXPERIMENTAL
Intervention: Community health advisors (CHAs) with family history of cancer
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Community health advisors (CHAs) with personal history of cancer
Number of subjects: 375
Study: 36892677

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin and paclitaxel administration
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intravenous administration (previously published data)
Number of subjects: 11
Study: 36892676

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m²
Number of subjects: 50
Study: 36892707

Group type: EXPERIMENTAL
Intervention: PAH therapy escalation
Number of subjects: 26
Study: 36892714

Group type: EXPERIMENTAL
Intervention: EQ-5D-Y-3L
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: EQ-5D-Y-5L
Number of subjects: 289
Study: 36892723

Group type: EXPERIMENTAL
Intervention: Omission of adjuvant radiotherapy in patients with pCR after NST
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Cancer Worry Scale
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Disease specific survival
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 595
Study: 36892745

Group type: EXPERIMENTAL
Intervention: DS-1205c plus osimertinib
Number of subjects: 13
Study: 36892753

Group type: EXPERIMENTAL
Intervention: Risankizumab 180 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Risankizumab 360 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 243
Study: 36892780

Group type: EXPERIMENTAL
Intervention: Reach Plus Message
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Reach Plus Phone
Number of subjects: 161

Group type: COMPARATOR
Intervention: Reach Plus
Number of subjects: 161
Study: 36892833

Group type: EXPERIMENTAL
Intervention: Regorafenib, ipilimumab, and nivolumab (RIN) at the RP2D of regorafenib dosed at 80 mg daily, ipilimumab 1 mg/kg every 6 weeks, and nivolumab 240 mg every 2 weeks.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regorafenib at 40 mg/d on cycle 1 and 80 mg/d on cycle 2 and beyond.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regorafenib, ipilimumab, and nivolumab (RIN) at the RP2D for patients without liver metastases.
Number of subjects: 39
Study: 36892847

Group type: COMPARATOR
Intervention: Alisertib 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg with standard-dose fulvestrant (arm 2)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Alisertib (arm 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Alisertib with fulvestrant (arm 2)
Number of subjects: 91
Study: 36892884

Group type: EXPERIMENTAL
Intervention: Positive Affect Treatment (PAT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Negative Affect Treatment (NAT)
Number of subjects: 85
Study: 36892916

Group type: EXPERIMENTAL
Intervention: Mild self-stigma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate to high self-stigma
Number of subjects: 0
Study: 36892929

Group type: EXPERIMENTAL
Intervention: Multidisciplinary exposure treatment
Number of subjects: 0
Study: 36892940

Group type: EXPERIMENTAL
Intervention: SPARX intervention
Number of subjects: 24
Study: 36892945

Group type: EXPERIMENTAL
Intervention: PrEP uptake among women with mild depression symptoms
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: PrEP refill requests among women with mild depression symptoms
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: PrEP adherence among women with mild depression symptoms
Number of subjects: 499
Study: 36893079

Group type: EXPERIMENTAL
Intervention: Conventional gait training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Robotic gait training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rated executive function (DEX)
Number of subjects: 45
Study: 36893091

Group type: EXPERIMENTAL
Intervention: Mastery-climate motor skills intervention (n = 70)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (n = 50)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mastery-climate motor skills intervention
Number of subjects: 120
Study: 36893205

Group type: EXPERIMENTAL
Intervention: Nordic walking training program plus education and usual care
Number of subjects: 114

Group type: COMPARATOR
Intervention: Educational and usual care only
Number of subjects: 114
Study: 36893207

Group type: EXPERIMENTAL
Intervention: Team'IT observational tool
Number of subjects: 23
Study: 36893453

Group type: EXPERIMENTAL
Intervention: TPO-RA discontinuation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TPO-RA rechallenge
Number of subjects: 48
Study: 36893575

Group type: EXPERIMENTAL
Intervention: Stable bra with compression
Number of subjects: 201

Group type: COMPARATOR
Intervention: Soft bra
Number of subjects: 201
Study: 36893777

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (CRP) quartiles
Number of subjects: 31245

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (LDLC) quartiles
Number of subjects: 31245
Study: 36893785

Group type: EXPERIMENTAL
Intervention: nvHAP prevention bundle (oral care, dysphagia screening and management, mobilisation, discontinuation of non-indicated proton-pump inhibitors, respiratory therapy)
Number of subjects: 361947
Study: 36893784

Group type: EXPERIMENTAL
Intervention: Single dose of oral arpraziquantel 50 mg/kg (cohort 1a)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Single dose of oral praziquantel 40 mg/kg (cohort 1b)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Single dose of oral arpraziquantel 50 mg/kg (cohort 2)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Single dose of oral arpraziquantel 50 mg/kg (cohort 3)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Single dose of oral arpraziquantel 60 mg/kg (cohort 4b)
Number of subjects: 288
Study: 36893804

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (14 studies, 5830 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions for higher risk individuals (9 studies, 1513 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions for unselected populations (6 studies, 3780 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (12 studies, 5253 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions for higher risk individuals (9 studies, 1473 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (5 studies, 1848 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (2 studies, 1668 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (3 studies, 325 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Home fall-hazard reduction interventions (3 studies, 946 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Vision improvement interventions (3 studies, 1489 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Vision improvement interventions (1 study, 597 participants)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Education intervention (1 study)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Education intervention (1 study, 110 participants)
Number of subjects: 8463
Study: 36893935

Group type: EXPERIMENTAL
Intervention: KE+CHO (573 mg KE/kg body mass plus 110 g glucose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CHO (110 g glucose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: KE+CHO
Number of subjects: 12

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 12
Study: 36893988

Group type: EXPERIMENTAL
Intervention: Parent +Family-based group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Newsletter +Family-based group
Number of subjects: 240
Study: 36894129

Group type: EXPERIMENTAL
Intervention: 30% chance of survival presented as text-only
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: 30% chance of survival presented in a static pictograph
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: 30% chance of survival presented in an iterative pictograph
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: 60% chance of survival presented as text-only
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: 60% chance of survival presented in a static pictograph
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: 60% chance of survival presented in an iterative pictograph
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Intuitive beliefs about chance of survival
Number of subjects: 1052
Study: 36894197

Group type: EXPERIMENTAL
Intervention: 6-day continuous peripheral nerve block with ropivacaine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 144
Study: 36894200

Group type: EXPERIMENTAL
Intervention: Clinical Ethics Committee (CEC) implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveys and interviews
Number of subjects: 0
Study: 36894201

Group type: EXPERIMENTAL
Intervention: Comprehensive menstrual health (MH) intervention including education, support, analgesics, and menstrual products.
Number of subjects: 303
Study: 36894238

Group type: EXPERIMENTAL
Intervention: Fava beans
Number of subjects: 0
Study: 36894239

Group type: COMPARATOR
Intervention: Acellular carbohydrate sources (e.g., flour-based whole-grain products)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Cellular carbohydrate sources (minimally processed foods with intact cellular structures)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-fat (LCHF) diet
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: All diets (Acellular, Cellular, LCHF)
Number of subjects: 193
Study: 36894248

Group type: EXPERIMENTAL
Intervention: Maternal BCC and Paternal BCC
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Maternal BCC
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Maternal BCC and Food Vouchers
Number of subjects: 92
Study: 36894250

Group type: EXPERIMENTAL
Intervention: HIGH carotenoid intake (13.1 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MED carotenoid intake (13.1 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOW carotenoid intake (13.1 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 20
Study: 36894249

Group type: EXPERIMENTAL
Intervention: Healthy US-Style Diet (H-US)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (Med)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Vegetarian Diet (Veg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 63
Study: 36894565

Group type: EXPERIMENTAL
Intervention: Osc+ (slow-paced breathing with HRV biofeedback)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Osc- (personalized strategies with HRV biofeedback)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Osc+
Number of subjects: 108

Group type: COMPARATOR
Intervention: Osc-
Number of subjects: 108
Study: 36894651

Group type: EXPERIMENTAL
Intervention: On-site DNA-based molecular diagnosis (GeneXpert)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Same-day smear microscopy
Number of subjects: 584
Study: 36894810

Group type: EXPERIMENTAL
Intervention: Intravenously administered indocyanine green (ICG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Machine learning methods for data classification
Number of subjects: 50
Study: 36894823

Group type: EXPERIMENTAL
Intervention: DFT/DATx15 extended depth of focus toric intraocular lens
Number of subjects: 35
Study: 36894877

Group type: EXPERIMENTAL
Intervention: POC targeted coagulopathy management and intraoperative administration of 5% albumin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (non-POC)
Number of subjects: 67
Study: 36894879

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 73
Study: 36894887

Group type: EXPERIMENTAL
Intervention: High pain group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low pain group
Number of subjects: 59
Study: 36894900

Group type: EXPERIMENTAL
Intervention: MTM intervention (N=46)
Number of subjects: 90
Study: 36894916

Group type: EXPERIMENTAL
Intervention: Patient-Derived Tumor Organoids (PDTO) derived from HNSCC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDTO co-cultured with autologous immune cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcriptomic and genetic analyses of PDTO
Number of subjects: 0
Study: 36894921

Group type: EXPERIMENTAL
Intervention: Glar/Exenatide
Number of subjects: 73

Group type: COMPARATOR
Intervention: Glar
Number of subjects: 73

Group type: COMPARATOR
Intervention: Glar/Lispro
Number of subjects: 73
Study: 36894938

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Dulaglutide 4.5 mg
Number of subjects: 5
Study: 36894940

Group type: EXPERIMENTAL
Intervention: Standardised treatment package for first-episode depression
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Neuroimaging data (MRI and EEG)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Brain Positron Emission Tomography (PET)
Number of subjects: 800
Study: 36894966

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study: 36894985

Group type: EXPERIMENTAL
Intervention: Self-sampled HPV testing, visualization of the cervix with acetic acid (VIA), cryotherapy, mobile colposcopy, thermal ablation, loop electrosurgical excision procedure (LEEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel diagnostic tests (QG-MPH®, Prevo-Check®, PT Monitor®)
Number of subjects: 0
Study: 36894992

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 12
Study: 36895006

Group type: EXPERIMENTAL
Intervention: BEAM program (10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (MoodMission)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BEAM program
Number of subjects: 0
Study: 36895062

Group type: EXPERIMENTAL
Intervention: Non-anthracycline HER2-targeted treatment regimen with echocardiograms every 6 months
Number of subjects: 190
Study: 36895157

Group type: EXPERIMENTAL
Intervention: Novel endovascular venous anastomotic device
Number of subjects: 158
Study: 36895163

Group type: EXPERIMENTAL
Intervention: Focal therapy (FT) using cryotherapy
Number of subjects: 28
Study: 36895330

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm eXtreme Gradient Boosting (XGBoost)
Number of subjects: 16736
Study: 36895331

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) combined with prednisone
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo combined with prednisone
Number of subjects: 116
Study: 36895483

Group type: EXPERIMENTAL
Intervention: Patient-specific 3-D surgical navigation system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 30
Study: 36895618

Group type: EXPERIMENTAL
Intervention: Community Qigong classes
Number of subjects: 14
Study: 36895801

Group type: EXPERIMENTAL
Intervention: CRE infections (cUTI, pneumonia, cIAI, BSI-OS)
Number of subjects: 235

Group type: COMPARATOR
Intervention: CSE controls
Number of subjects: 235
Study: 36896366

Group type: EXPERIMENTAL
Intervention: Exergaming intervention (n=21)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard exercise protocol (control group, n=25)
Number of subjects: 52
Study: 36896702

Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 662
Study: 36896716

Group type: EXPERIMENTAL
Intervention: In-hospital observation on oral diuretics (OOD)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control (no in-hospital OOD)
Number of subjects: 468
Study: 36896967

Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment of malaria (ISTp)
Number of subjects: 1786

Group type: COMPARATOR
Intervention: Routine ANC (control)
Number of subjects: 1786
Study: 36897008

Group type: EXPERIMENTAL
Intervention: DPMAS with sequential low-volume plasma exchange (LPE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comprehensive medical treatment (Control)
Number of subjects: 50
Study: 36897127

Group type: EXPERIMENTAL
Intervention: SNP-based noninvasive prenatal screening results suspicious for maternal malignancy
Number of subjects: 2004428
Study: 36897140

Group type: EXPERIMENTAL
Intervention: Scheduled intravenous ketorolac (30 mg every 6 hours)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (30 mg every 6 hours)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Scheduled intravenous ketorolac
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Scheduled intravenous ketorolac and Placebo
Number of subjects: 148
Study: 36897162

Group type: EXPERIMENTAL
Intervention: Concomitant cancer and SUI surgery
Number of subjects: 532

Group type: COMPARATOR
Intervention: Cancer surgery alone
Number of subjects: 532
Study: 36897180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg
Number of subjects: 1830
Study: 36897182

Group type: EXPERIMENTAL
Intervention: Endurance of cervical, scapular, trunk, and upper extremity muscles
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Endurance of cervical flexor, anterior trunk flexor, and upper extremity muscles
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Endurance of upper extremity, scapular region, and trunk muscles
Number of subjects: 36
Study: 36897202

Group type: EXPERIMENTAL
Intervention: Patient-Specific Functional Scale (PSFS)
Number of subjects: 32